contents http://www.kidney-international.
org
& 2012 KDIGO
TABLES
18 Table 1. Implications of the strength of a recommendation
19 Table 2. Staging of AKI
21 Table 3. Comparison of RIFLE and AKIN criteria for diagnosis and classification of AKI
21 Table 4. Cross-tabulation of patients classified by RIFLE vs. AKIN
22 Table 5. Causes of AKI and diagnostic tests
23 Table 6. Causes of AKI: exposures and susceptibilities for non-specific AKI
28 Table 7. AKI diagnosis
29 Table 8. Overview of the approaches to determine baseline SCr in the application of RIFLE classification in previous
studies
29 Table 9. Estimated baseline SCr
30 Table 10. AKI staging
33 Table 11. Definitions of AKI, CKD, and AKD
33 Table 12. Examples of AKI, CKD, and AKD based on GFR and increases in SCr
35 Table 13. Markers of kidney damage in AKD and CKD
35 Table 14. Integrated approach to interpret measures of kidney function and structure for diagnosis of AKI, AKD, and CKD
73 Table 15. CI-AKI risk-scoring model for percutaneous coronary intervention
77 Table 16. Additional radiological measures to reduce CI-AKI
91 Table 17. Potential applications for RRT
91 Table 18. Fluid overload and outcome in critically ill children with AKI
97 Table 19. Overview of the advantages and disadvantages of different anticoagulants in AKI patients
104 Table 20. Catheter and patient sizes
107 Table 21. Typical setting of different RRT modalities for AKI (for 70-kg patient)
108 Table 22. Theoretical advantages and disadvantages of CRRT, IHD, SLED, and PD
112 Table 23. Microbiological quality standards of different regulatory agencies
FIGURES
14 Figure 1. The RIFLE criteria for AKI
20 Figure 2. Overview of AKI, CKD, and AKD
20 Figure 3. Conceptual model for AKI
25 Figure 4. Stage-based management of AKI
26 Figure 5. Evaluation of AKI according to the stage and cause
34 Figure 6. Chronic Kidney Disease Epidemiology Collaboration cohort changes in eGFR and final eGFR corresponding to
KDIGO definition and stages of AKI
34 Figure 7. GFR/SCr algorithm
38 Figure 8. Conceptual model for development and clinical course of AKI
48 Figure 9. Effect of furosemide vs. control on all-cause mortality
48 Figure 10. Effect of furosemide vs. control on need for RRT
51 Figure 11. Effect of low-dose dopamine on mortality
52 Figure 12. Effect of low-dose dopamine on need for RRT
73 Figure 13. Sample questionnaire
78 Figure 14. Risk for contrast-induced nephropathy
81 Figure 15. Bicarbonate vs. saline and risk of CI-AKI
85 Figure 16. NAC and bicarbonate vs. NAC for risk of CI-AKI
96 Figure 17. Flow-chart summary of recommendations
Additional information in the form of supplementary materials can be found online at http://www.kdigo.org/clinical_practice_guidelines/AKI.php
iv Kidney International Supplements (2012) 2, iv
